{"schema_version":"secwatch.filing_event.v1","accession":"0001388658-26-000070","form_type":"8-K","ticker":"IRTC","cik":"0001388658","company_name":"iRhythm Holdings, Inc.","filed_at":"2026-08-06T20:15:12+00:00","discovered_at":"2026-08-06T20:16:00.464510+00:00","generated_at":"2026-08-06T20:19:20.653508+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"iRhythm Q2 revenue $224M (+20% YoY), raises guidance; acquires VitalConnect for $287.5M","bullets":["Revenue $224.2M (+20.1% YoY); net loss $0.4M vs $14.2M loss; adjusted EBITDA $43.3M (19.3% margin).","FY2026 revenue guidance raised to $880-890M; adjusted EBITDA margin 13-14%.","Acquiring VitalConnect for ~$287.5M ($237.5M cash + $50M stock); expected close by end of 2026.","Settled Baxter patent litigation with $50M payment; cross-license and 6-year covenant not to sue.","FDA cleared third-gen algorithm; expected to cut clinician review time ~50% and save $100M over 5 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001388658-26-000070","json":"https://secwatch.observer/filing/0001388658-26-000070.json","markdown":"https://secwatch.observer/filing/0001388658-26-000070.md","text":"https://secwatch.observer/filing/0001388658-26-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388658/000138865826000070/0001388658-26-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388658/000138865826000070/irtc-20260731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:19:20.653508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}